Home/Filings/4/0001181431-09-006166
4//SEC Filing

Transcept Pharmaceuticals Inc 4

Accession 0001181431-09-006166

CIK 0001178711operating

Filed

Feb 2, 7:00 PM ET

Accepted

Feb 3, 3:29 PM ET

Size

7.9 KB

Accession

0001181431-09-006166

Insider Transaction Report

Form 4
Period: 2009-01-30
Transactions
  • Other

    Common Stock

    2009-01-30+1,103,2831,103,283 total(indirect: See Note 1)
Holdings
  • Common Stock

    (indirect: See Note 2)
    980,143
Footnotes (4)
  • [F1]The Reporting Person is an individual manager of NEA GP 12, LLC ("NEA 12 GP"), the sole general partner of NEA Partners 12, Limited Partnership ("NEA Partners 12"), which is the sole general partner of New Enterprise Associates 12, Limited Partnership ("NEA 12"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 12 shares in which the Reporting Person has no actual pecuniary interest therein.
  • [F2]The Reporting Person is a general partner of NEA Partners 10, Limited Partnership, the sole general partner of New Enterprise Associates 10, Limited Partnership ("NEA 10"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 10 shares in which the Reporting Person has no actual pecuniary interest therein.
  • [F3]NEA 10 previously held 4,900,715 shares of common stock of Novacea, Inc. ("Novacea"). On January 30, 2009, Novacea completed a merger (the "Merger") with Transcept Pharmaceuticals, Inc., whereby Transcept Pharmaceuticals, Inc. became a wholly-owned subsidiary of Novacea. After completion of the Merger, Novacea was renamed Transcept Pharmaceuticals, Inc. Prior to the Merger, the common stock of Novacea split 1-for-5, resulting in NEA 10's ownership of 980,143 shares of Novacea's common stock.
  • [F4]As consideration for the Merger, NEA 12 received 0.14134 shares of Novacea common stock in exchange for each share of Transcept Pharmaceuticals, Inc. capital stock held by NEA 12 prior to the Merger.

Documents

1 file

Issuer

Transcept Pharmaceuticals Inc

CIK 0001178711

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001178711

Filing Metadata

Form type
4
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 3:29 PM ET
Size
7.9 KB